Steris PLC (STE)
| Market Cap | 16.13B |
| Revenue (ttm) | 3.02B |
| Net Income (ttm) | 422.29M |
| Shares Out | 85.05M |
| EPS (ttm) | 4.93 |
| PE Ratio | 38.29 |
| Forward PE | 26.32 |
| Dividend | $1.60 |
| Dividend Yield | 0.85% |
| Trading Day | January 22 |
| Last Price | $188.76 |
| Previous Close | $188.33 |
| Change ($) | 0.43 |
| Change (%) | 0.23% |
| Day's Open | 187.64 |
| Day's Range | 186.90 - 189.54 |
| Day's Volume | 402,361 |
| 52-Week Range | 107.01 - 202.81 |
STERIS to Host a Conference Call for Fiscal 2021 Third Quarter Financial Results on February 3, 2021
DUBLIN, IRELAND, Jan. 19, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2021 third quar...
Steris is a long-term value creator, which combines organic growth with bolt-on acquisitions. The company started 2021 with a big deal, acquiring Cantel in a multi-billion transaction.
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Cantel M...
STERIS (STE) expects to strengthen and expand its endoscopy offerings along with extending into a new customer territory via the Cantel Medical buyout.
NEW YORK, Jan. 12, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Cantel Medical Corporation (NYSE: CMD) ("Cantel") and its board of directors con...
Shares of Cantel Medical Corp. rose 1.8% in premarket trading Tuesday, after the infection prevention products company announced an agreement to be acquired by Ireland-based Steris PLC in a ca...
DUBLIN, IRELAND and LITTLE FALLS, N.J, Jan. 12, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) and Cantel Medical Corp (NYSE:CMD) (“Cantel”) today announced that S...
DUBLIN, IRELAND, Jan. 07, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced that the Company will be publicly webcasting presentations made by Walt Ro...
Steris (STE) reported earnings 30 days ago. What's next for the stock?
DUBLIN, IRELAND, Nov. 18, 2020 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced that is has completed the previously announced acquisition of Key Surgical...
3 Best Buys from the Prospering Medical Instruments Industry
STERIS plc's (STE) CEO Walter Rosebrough on Q2 2021 Results - Earnings Call Transcript
STERIS plc (STE) CEO Walter Rosebrough on Q2 2021 Results - Earnings Call Transcript
STERIS' (STE) second-quarter fiscal 2021 results reflect strong performance by the Life Sciences and the Applied Sterilization Technologies segments despite the coronavirus-led economic crisis.
Steris (STE) delivered earnings and revenue surprises of 19.35% and 7.23%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
DUBLIN, IRELAND , Nov. 02, 2020 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2021 second quarter ended September 30,...
Several medical product stocks have come up with bullish earnings reports so far this reporting cycle. Let's see how STE, HSIC, PACB, INSP are poised ahead of their announcements.
Within Life Sciences, STERIS (STE) might have registered benefit from pharma customers on growing vaccines and biologics businesses in Q2.
COVID-19 has heightened the demand for companies that specialize in infection control.
Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DUBLIN, IRELAND, Oct. 20, 2020 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2021 second quar...
Steris (STE) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Steris PLC STE, +1.18% said Tuesday it has agreed to acquire Key Surgical, a portfolio company of Water Street Healthcare Partners LLC for $850 million. Dublin, Ireland-based Steris expects th...
DUBLIN, IRELAND, Oct. 06, 2020 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced that the Company has signed a definitive agreement to purchase Key Surgica...
The U.S. presidential election is less than 50 days away and the health care sector could prove to be the most impacted. On Monday, Chantico Global CEO Gina Sanchez laid out on CNBC’s “Trading...
STERIS (STE) is optimistic about maintaining growth momentum on broader product and service portfolio along with strength in its Life Sciences business.
Steris (STE) reported earnings 30 days ago. What's next for the stock?
5 Dividend Increases For The Week Of August 23rd With 1 Dividend King
STERIS plc (STE) CEO Walter Rosebrough on Q1 2021 Results - Earnings Call Transcript
STERIS' (STE) first-quarter fiscal 2021 results reflect strong performance by the Life Sciences segment despite the coronavirus-led economic crisis.
Steris (STE) delivered earnings and revenue surprises of 35.05% and 4.55%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
• First quarter revenue declines low-single digits due to reduction in deferrable procedures • First quarter net income grows low-single digits driven by margin expansion •...
STERIS (STE) registers declines in Healthcare Products with neutral performance in Life Science and AST in April, which is likely to have impacted Q1 earnings.
DUBLIN, IRELAND, July 22, 2020 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2021 first qua...
As a major landmark for STERIS (STE), in fiscal 2020, the company joined the coveted S&P 500 Index.
Steris and Fortive are on the rise, thanks in part to their medical devices used to decontaminate N95 or N95-equivalent respirators.
DUBLIN, IRELAND, May 26, 2020 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has issued another Emerg...
STERIS' (STE) fourth-quarter fiscal 2020 results reflect strong segmental performance despite the coronavirus-led economic crisis.
STERIS' (STE) CEO Walt Rosebrough on Q4 2020 Results - Earnings Call Transcript
Steris (STE) delivered earnings and revenue surprises of 4.46% and 4.39%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
DUBLIN, IRELAND, May 13, 2020 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2020 fourth quarter ended March 31, 2020...
Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DUBLIN, IRELAND, April 10, 2020 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has issued an Emergenc...
Investors continue to be optimistic about STERIS (STE) on its strong segmental growth in the third quarter of 2020.
Despite coronovirus upsurge, a handful of S&P 500 stocks rallied last week. Some of them carry a favorable Zacks Rank with strong potential for future growth.
STERIS (STE) continues to register stellar organic growth across all four operating segments.
Studies have shown that a majority of stocks had seen acceleration in earnings before a rally in stock price.
Steris shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 76 to 82. The post Steris Meets 80-Plus Relative Strength Rating Benchmark appeared first on ...
Steris (STE) reported earnings 30 days ago. What's next for the stock?
About STE
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including... [Read more...]
| Industry Medical Instruments & Supplies | IPO Date Jun 1, 1992 |
| CEO Walter Rosebrough | Employees 13,000 |
| Stock Exchange NYSE | Ticker Symbol STE |
Financial Performance
In 2019, Steris's revenue was $3.03 billion, an increase of 8.94% compared to the previous year's $2.78 billion. Earnings were $407.61 million, an increase of 34.06%.
Analyst Forecasts
According to 7 analysts, the average rating for Steris stock is "Buy." The 12-month stock price forecast is 221.33, which is an increase of 17.25% from the latest price.